Ribupatide, also known as HRS9531 or KAI-9531-T, is the once-daily oral GLP-1/GIP dual receptor agonist Hengrui Pharma developed in China and licensed to Kailera Therapeutics for global rights. The drug shares its dual incretin mechanism with Lilly's injectable tirzepatide, but in tablet form, positioning it directly against Lilly's Foundayo (orforglipron) and Structure's aleniglipron in the oral-incretin contest.
Phase 2 data published in February 2026 showed up to 12.1% mean weight loss at 26 weeks in 166 Chinese adults with obesity, with no observed plateau and up to 38.6% of participants reaching at least 15% weight loss. Vomiting was reported in 11.4% (25 mg) and 7.5% (50 mg) of dose arms. Hengrui plans to advance ribupatide rapidly into Phase 3 in China, while Kailera intends to launch a global Phase 2 in 2026.
Stories here cover ribupatide trial readouts and the China-led oral-incretin race. See #hengrui, #kailera-therapeutics, and #oral-glp-1 for adjacent threads.
Kailera Therapeutics (NASDAQ: KLRA) continues through September 2026 the ramp toward global ex-China Phase 3 initiation for ribupatide (a once-weekly subcutaneous injection GIP/GLP-1/glucagon triple agonist peptide licensed globally ex-China from Hengrui Pharma under the May 2024 up-to-$5+ billion collaboration). The China Phase 3 program is complete with mean weight loss of nearly 18% at 48 weeks in Chinese overweight and obese adults. Ribupatide oral formulation (HRS-7535, licensed as KAI-7535 to Kailera ex-China) had NMPA marketing authorization applications accepted in China September 2, 2026 for both obesity and type 2 diabetes based on the OUTSTAND-1 and OUTSTAND-2 Phase 3 trials. The global ex-China ribupatide Phase 3 program is designed to run against Eli Lilly's retatrutide (28.3% weight loss in TRIUMPH-1) as the second-in-class triple-agonist option, and Kailera has signaled ambition to file in the U.S. within 12-18 months of Phase 3 readout. Ribupatide would be the third Chinese-origin GLP-1-class asset to reach U.S. clinical development, following Innovent-Lilly mazdutide and Sciwind-Pfizer ecnoglutide.
Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide, with Kailera's US Phase 3 planned H1 2027); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.
Kailera Therapeutics (NASDAQ: KLRA) received sweeping positive analyst coverage following its August 12, 2026 Q2 2026 earnings report. Kailera confirmed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T) and global Phase 3 obesity trials planned for H1 2027. Analyst response: according to 6 analysts, the average rating for KLRA stock is Strong Buy, with a 12-month average price target of $42.60 representing 82.83% upside from the $17.95-$19.50 trading range on August 13-14. Named ratings include TD Cowen at Buy with a $57 price target, Evercore ISI at Outperform, and William Blair at Outperform. The company holds cash, cash equivalents, and marketable securities expected to support execution of multiple clinical milestones with runway into mid-2028. Ribupatide mechanism: a once-weekly GLP-1/GIP dual agonist peptide (mechanistically similar to Eli Lilly's tirzepatide) with the ribupatide injection Phase 2 trial reaching 23.6% mean weight loss at 8 mg over 36 weeks, and the oral formulation reaching up to 12.1% weight loss with 38.6% of participants achieving at least 15% loss at Week 26 in Hengrui's Phase 2 trial. The Phase 2b high-dose injection trial in obesity is fully enrolled with data anticipated in mid-2027.
Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.
Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.